Alto Neuroscience (ANRO) Convertible Debt (2024 - 2026)

Alto Neuroscience (ANRO) has 3 years of Convertible Debt data on file, last reported at $2.3 million in Q1 2026.

• For the quarter ending Q1 2026, Convertible Debt rose 92.82% year-over-year to $2.3 million; the trailing twelve-month figure through Mar 2026 stood at $2.3 million (up 92.82% YoY), and the FY2025 full-year result was $2.2 million, up 70.78% from the prior year.
• Convertible Debt climbed to $2.3 million in Q1 2026, from $2.2 million in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $2.3 million in Q1 2026 to a low of $1.2 million in Q1 2025.
• A 3-year average of $1.8 million and a median of $2.0 million in 2025 frame the typical range for Convertible Debt.
• Across the five-year window, Convertible Debt soared 63.64% in 2025 and surged 92.82% in 2026, its largest moves.
• Tracing ANRO's Convertible Debt over 3 years: stood at $1.3 million in 2024, then surged by 70.78% to $2.2 million in 2025, then climbed by 4.85% to $2.3 million in 2026.
• Business Quant data shows ANRO's Convertible Debt at $2.3 million in Q1 2026, $2.2 million in Q4 2025, and $2.1 million in Q3 2025.